Skip to main content

Table 1 Clinical presentations and demographic data of 682 patients with pre-operative diagnosis of ductal carcinoma in situ (DCIS)

From: Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI

N = 682 Mean ± SD (%)
Age, year 52.3 ± 10.1
Location  
Right 328(48.1)
Left 354(51.9)
Biopsy method(N/A = 3)  
CNB 421(62)
Stereotactic biopsy 167(24.6)
Excisional biopsy 88(12.9)
MMG 3(0.4)
Tumor size, cm 2.2 ± 2.5
Lymph node(N/A = 33)  
Positive 49(7.6)
Negative 600(92.4)
Stage (N/A = 33)  
0 390(60.1)
I 183(28.2)
II 65(10.0)
III 11(1.7)
Lymph node stage(N/A = 83)  
N0 549(91.7)
N1 40(6.7)
N2 7(1.2)
N3 3(0.5)
Grade(N/A = 74)  
I 76(12.5)
II 337(55.4)
III 195(32.1)
ER(N/A = 24)  
Positive 484(73.6)
Negative 174(26.4)
PR(N/A = 33)  
Positive 438(67.5)
Negative 211(32.5)
HER-2(N/A = 203)  
Positive 178(37.2)
Negative 301(62.8)
Post-OP pathology  
DCIS 412(60.4)
LCIS 5(0.7)
DCIS + LCIS 7(1.0)
DCIS + microinvasive 5(0.7)
DCIS + tubular carcinoma 1(0.1)
DCIS + mucinous carcinoma 3(0.4)
IDC + DCIS 228(33.4)
IDC 9(1.3)
ILC 1(0.1)
Other 11(1.6)
  1. NA not available, CNB core needle biopsy, MMG mammography guided biopsy, ER estrogen receptor, PR progesterone receptor, HER-2 human epithelial receptor type 2, OP operation, DCIS ductal carcinoma in situ, LCIS lobular carcinoma in situ, ILC infiltrating lobular carcinoma, IDC infiltrating ductal carcinoma